Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Pharma name with multiple recent catalysts: late May and June brought several U.S. approvals and positive late-stage updates including TRUQAP, BAXFENDY, IMFINZI, Datroway, IMFINZI/IMJUDO, and camizestrant SERENA-6 data; shares gained about 9.6% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High Profitability ⢠Tight Liquidity ⢠Rising Leverage AZN delivers strong profitability and cash flow, but elevated leverage, tight liquidity, intangible-heavy assets, and a demanding valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Below average ⢠Support test ⢠Weak momentum Support Level: $156.45â$157.25 Resistance Level: $164.50â$166.30 AZN is weakening after its late-August peak, with $156.45â$157.25 support critical; hold it for stabilization, while reclaiming $162.20 would improve momentum.
Sentiment & News
Key News Insights: ⢠Tagrisso Phase 3 ⢠FDA accelerated approval ⢠Mixed trial results AstraZeneca's advancing oncology and respiratory programs are offset by trial setbacks, divided analyst sentiment and recent share weakness, creating a mixed near-term outlook.
AI Summary
AZN remains a high-quality, cash-generative pharma, but the investment case has shifted to proving that late-stage oncology and respiratory wins translate into revenue fast enough to offset clinical failures and rising debt; consider waiting for evidence of launch traction or a technical recovery above $162 before adding exposure.
Description
AstraZeneca PLC is a global biopharmaceutical company engaged in the discovery, development, manufacture and commercialization of prescription medicines across oncology, cardiovascular, renal and metabolic (CVRM), respiratory, vaccines and rare diseases. Its commercial portfolio and pipeline span established brands and newer therapies for core therapeutic areas, and the company distributes products through primary and specialty care channels across the UK, Europe, the Americas, Asia, Africa and Australasia. Incorporated in 1992 and headquartered in Cambridge, UK, AstraZeneca maintains external R&D collaborations with partners such as Neurimmune AG, BenevolentAI, Lunit and Absci Corporation.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 2 | Jul 9 | AZN | AstraZeneca PLC | Pharma name with multiple recent catalysts: late May and June brought several U.S. approvals and positive late-stage updates including TRUQAP, BAXFENDY, IMFINZI, Datroway, IMFINZI/IMJUDO, and camizestrant SERENA-6 data; shares gained about 9.6% over 21 trading days. | Closed | -8.5% |
| Feb 20 | Feb 27 | AZN | AstraZeneca PLC | Recent high-impact drug catalysts (ENHERTU new 1L breast cancer approval, Baxdrostat NDA Priority Review) plus reiterated 2026 growth guidance and a ~19% 21-day price run with shares ~9% above the 21-day SMA and breaking out of the 188â195 range support near-term continuation for a disciplined momentum trade. | Closed | +2.1% |